<DOC>
	<DOC>NCT00135356</DOC>
	<brief_summary>The purpose of this clinical research study is to learn if human immunodeficiency virus (HIV)-infected subjects with abdominal fat accumulation on their highly active antiretroviral treatment (HAART) regimen have better changes in fat distribution after switching to atazanavir-ritonavir than those remaining on their current protease inhibitor boosted HAART regimen.</brief_summary>
	<brief_title>Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>HIV1 infected on HAART regimen containing 2 NRTI and boosted PI for at least 12 weeks prior to screening. Subjects may not have experienced virological failure to more than one prior PIcontaining regimen. Must be able to swallow tablets Viral load &lt;400 c/mL at screening and stable for at least 6 months Signs of fat redistribution and lipohypertrophy (abdominal) Waist to Hip Ratio &gt;0.90 and Waist Circumference &gt;88.2 cm for men and Waist Circumference &gt;75.3 for women Pregnant or breastfeeding women New HIVrelated opportunistic infections Active alcohol or substance use Grade 4 lab toxicity History of taking atazanavir (ATV) Prohibited therapies, including nonnucleoside reverse transcriptase inhibitors (NNRTI)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>HIV infections</keyword>
</DOC>